

Supplementary Table 2 - Retail medicine market in Italy: comparison 2017 vs. 2016

Italy		Net spending 2017 (€)	DDD x 1000 inh. 2017	Δ% 2017 vs. 2016	
				Net spending (€)	DDD x 1000 inh.
1	C10AA07 ROSUVASTATIN	217,412,592.00	145.15	-3.47	-2.95
2	A02BC02 PANTOPRAZOLE	195,390,514.61	246.41	0.50	1.34
3	A11CC05 CHOLECALCIFEROL	178,188,579.89	1,595.35	29.55	24.65
4	C10AA05 ATORVASTATIN	173,340,792.38	498.61	8.27	8.95
5	C10BA02 SIMVASTATIN/EZETIMIBE	163,593,162.50	49.48	6.31	6.44
6	R03AK06 SALMETEROL/FLUTICASONE	141,324,726.56	43.53	-14.68	-14.29
7	A02BC03 LANSOPRAZOLE	134,009,509.79	186.72	-8.19	-7.13
8	J01CR02 AMOXICILLIN AND INHIBITOR BL	129,887,530.13	104.32	-1.41	-0.54
9	A02BC01 OMEPRAZOLE	128,279,763.02	204.99	-5.99	-3.92
10	B01AB05 ENOXAPARIN	109,371,336.94	26.86	-14.06	-13.62
11	R03AK08 FORMOTEROL AND BECLOMETHASONE	108,075,441.00	38.00	6.65	6.91
12	A02BC05 ESOMEPRAZOLE	106,832,701.90	152.23	-0.39	2.46
13	C10AX09 EZETIMIBE	99,526,737.00	35.66	25.16	25.34
14	G04CB02 DUTASTERIDE	99,044,401.20	89.46	-27.80	2.63
15	C10AX06 OMEGA-3-TRIGLYCERIDE INCLUDED	92,598,935.26	47.76	6.53	7.01
16	A10AB04 INSULIN LISPRO	91,424,592.13	40.76	5.70	6.19
17	A07EC02 MESALAZINE	87,816,693.38	51.78	3.56	3.92
18	R03BB04 TIOTROPIUM BROMIDE	87,481,854.27	34.32	-17.78	-11.12
19	R03AK10 FLUTICASONE/VILANTEROL	84,504,278.00	30.66	27.32	24.68
20	C09DB02 OLMESARTAN MEDOXOMIL AND AMLOD	82,806,318.13	57.75	8.22	13.01
21	C09AA05 RAMIPRIL	80,740,352.17	745.61	0.38	0.13
22	A10AB05 INSULIN ASPART	78,905,881.50	35.15	-2.37	-2.24
23	C10AA01 SIMVASTATIN	78,035,082.04	173.68	-2.85	-2.81
24	N03AX14 LEVETIRACETAM	72,013,650.15	22.26	7.32	7.21
25	C07AB07 BISOPROLOL	70,875,161.08	119.66	8.14	6.46
26	A07AA11 RIFAXIMIN	69,648,000.45	22.15	1.24	0.98
27	S01ED51 TIMOLOL- ASSOCIATIONS	67,403,535.81	67.68	2.66	1.40
28	N02AB03 FENTANYL	65,962,877.03	7.32	4.82	4.41
29	C08CA01 AMLODIPINE	62,806,169.09	318.73	-1.32	-1.69
30	A10BA02 METFORMIN	61,966,864.21	256.33	6.72	2.64

Supplementary Table 3 - Retail Medicine Market in Piedmont: comparison 2017 vs. 2016

Piedmont		Net spending 2017 (€)	DDD x 1000 inh. 2017	Δ% 2017 vs. 2016	
				Net spending (€)	DDD x 1000 inh.
1	C10AA07 ROSUVASTATIN	16,998,460.38	153.00	-5.90	-5.07
2	A02BC02 PANTOPRAZOLE	16,084,926.18	234.70	-1.37	-0.44
3	A11CC05 CHOLECALCIFEROL	12,416,272.32	1,428.29	27.66	19.55
4	C10AA05 ATORVASTATIN	12,171,399.20	423.09	7.41	8.59
5	R03AK06 SALMETEROL/FLUTICASONE	9,945,987.78	40.49	-15.74	-15.99
6	C10BA02 SIMVASTATIN/EZETIMIBE	9,738,493.03	40.00	6.50	6.56
7	A02BC05 ESOMEPRAZOLE	9,656,084.24	153.58	-4.32	-1.45
8	J01CR02 AMOXICILLIN AND INHIBITOR BL	8,946,797.02	89.25	-2.32	-1.32
9	A02BC01 OMEPRAZOLE	8,842,322.98	172.80	-7.46	-6.07
10	R03BB04 TIOTROPIUM BROMIDE	8,372,373.91	44.06	-17.18	-10.96
11	R03AK08 FORMOTEROL AND BECLOMETHASONE	8,112,860.61	38.50	7.23	7.34
12	A02BC03 LANSOPRAZOLE	7,291,265.68	119.51	-10.08	-9.62
13	G04CB02 DUTASTERIDE	7,190,050.54	85.87	-27.51	1.98
14	C10AX09 EZETIMIBE	6,844,189.28	33.19	24.52	24.68
15	A10AB05 INSULIN ASPART	6,822,739.50	41.04	-1.13	-1.59
16	A07AA11 RIFAXIMIN	6,366,788.22	24.60	8.04	1.67
17	A10AB04 INSULIN LISPRO	6,218,724.21	37.37	4.57	4.31
18	R03AK10 FLUTICASONE/VILANTEROL	6,100,115.36	29.86	25.89	23.04
19	A07EC02 MESALAZINE	6,005,169.69	48.69	4.57	4.20
20	N02AA55 OXYCODONE AND NALOXONE	5,987,751.72	6.68	6.39	7.32
21	N03AX14 LEVETIRACETAM	5,911,772.83	24.56	5.62	5.59
22	C09AA05 RAMIPRIL	5,854,970.84	649.36	1.32	0.94
23	S01ED51 TIMOLOL- ASSOCIATIONS	5,788,761.50	76.70	2.34	1.25
24	C10AA01 SIMVASTATIN	5,556,591.21	152.04	-2.69	-2.59
25	H05AA02 TERIPARATIDE	5,456,474.22	2.67	101.69	103.92
26	L02BG04 LETROZOLE	5,274,001.56	19.17	9.22	8.85
27	N02AX06 TAPENTADOL	5,180,879.78	6.67	15.45	15.48
28	B01AC06 ACETYLSALICYLIC ACID	5,173,477.79	738.25	2.93	-0.77
29	C07AB12 NEBIVOLOL	5,164,923.77	186.87	2.05	1.66
30	N02AB03 FENTANYL	5,147,755.93	9.62	3.95	5.32

Supplementary Table 4 - Retail medicine market in ASL CN2: comparison 2017 vs. 2016

ASL CN2		Net spending 2017 (€)	DDD x 1000 inh. 2017	Δ% 2017 vs. 2016	
				Net spending (€)	DDD x 1000 inh.
1	A02BC02 PANTOPRAZOLE	757,018.41	285.56	-5.46	-4.46
2	C10AA05 ATORVASTATIN	470,389.25	423.96	8.22	8.88
3	C10AA07 ROSUVASTATIN	440,816.20	101.86	-8.58	-7.59
4	C10BA02 SIMVASTATIN/EZETIMIBE	359,441.99	37.68	-0.64	-0.71
5	J01CR02 AMOXICILLIN AND INHIBITOR BL	355,679.09	90.31	-2.59	-1.87
6	R03AK06 SALMETEROL/FLUTICASONE	345,528.35	37.08	-14.52	-14.87
7	R03BB04 TIOTROPIUM BROMIDE	336,064.21	45.00	-7.00	-0.97
8	C10AA01 SIMVASTATIN	303,110.67	212.71	-4.61	-3.03
9	A07AA11 RIFAXIMIN	285,641.76	28.34	6.38	-0.18
10	S01ED51 TIMOLOL- ASSOCIATIONS	265,298.97	85.02	14.34	5.76
11	R03AK08 FORMOTEROL AND BECLOMETHASONE	263,490.80	32.12	3.96	3.93
12	A02BC05 ESOMEPRAZOLE	253,877.26	107.88	-4.61	-0.81
13	N02AA55 OXYCODONE AND NALOXONE	244,471.89	6.87	6.38	7.96
14	L02BG04 LETROZOLE	240,599.96	22.69	14.34	13.61
15	N03AX14 LEVETIRACETAM	228,636.31	24.44	8.13	8.79
16	R03AK10 FLUTICASONE/VILANTEROL	227,591.66	28.49	57.62	53.22
17	C10AX09 EZETIMIBE	224,734.67	27.90	15.38	15.39
18	A02BC03 LANSOPRAZOLE	223,809.02	93.61	-11.52	-11.54
19	C07AB12 NEBIVOLOL	223,460.97	208.13	-0.36	-0.70
20	A02BC01 OMEPRAZOLE	220,476.20	110.79	-10.01	-8.35
21	C08CA12 BARNIDIPINE	219,550.95	91.18	4.40	3.13
22	A07EC02 MESALAZINE	215,548.51	45.80	5.54	4.39
23	A11CC05 CHOLECALCIFEROL	204,667.14	2,041.63	20.38	18.64
24	A10AB05 INSULIN ASPART	203,822.32	31.26	-2.05	-2.60
25	G04CA02 TAMSULOSIN	203,530.56	188.82	1.46	1.62
26	A10BA02 METFORMIN	195,798.30	257.40	11.35	6.90
27	N02AB03 FENTANYL	191,412.88	10.11	-3.87	-3.06
28	N03AG01 VALPROIC ACID	191,026.23	33.59	2.69	-1.71
29	B01AC06 ACETYLSALICYLIC ACID	186,192.68	648.80	3.29	-1.38
30	G04CB02 DUTASTERIDE	184,400.26	57.61	-26.94	4.39